Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hanmian Granules (鼾眠颗粒) is a Traditional Chinese Medicine (TCM) botanical drug candidate currently in Phase II clinical development for the treatment of pediatric adenoid hypertrophy. The formulation is specifically designed to address the "lung and spleen qi deficiency, phlegm and blood stasis" syndrome, a common TCM diagnosis for children suffering from enlarged adenoids and associated symptoms such as snoring and mouth breathing. The drug is being co-developed by Shandong Kangzhonghong Pharmaceutical Technology Development and Jichuan Pharmaceutical Group. As a TCM granule, it likely comprises a multi-component herbal extract aimed at tonifying qi, resolving phlegm, and dissipating blood stasis to reduce adenoid volume and improve respiratory symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hanmian Granules.